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366Alveolar Macrophage
in the Driver’s Seat
Although alveolar macrophages are normally quies-
cent to prevent damaging the alveoli, in this issue
of Immunity, Takabayshi et al. (2006) demonstrate
that alveolar macrophages can self-regulate their
function on demand to mount an appropriate immune
response.
The function of the lung is to allow the uptake of oxygen
and the excretion of carbon dioxide. Gas exchange oc-
curs in lung alveoli, which are made up of thin type I al-
veolar epithelial cells (AECs) and more cuboidal type II
AECs that produce surfactant and have self-renewal
and differentiation potential. Lung capillaries are situ-
ated in close approximation to the type I cells, sepa-
rated only by a 0.2 mm thick fused basement membrane,
allowing the easy diffusion of gas. With its large surface
area, the lung is exposed to many environmental chal-
lenges and is a portal of entry for many pathogens be-
cause the air we breathe is contaminated with infectious
agents, toxic gases, and (fine) particulate matter. The in-
haled microbes and inhaled toxic substances can then
gain easy access to the bloodstream across the delicate
alveolar-capillary membrane. Defense of this barrier is
not easy and needs to be tightly controlled because
too much edema, inflammation, and cellular recruitment
will lead to thickening of the alveolar wall and will jeop-
ardize the diffusion of gases. Considering the large sur-
face area of the respiratory epithelium and the volume of
air inspired on a daily basis, it is remarkable that there is
so little inflammation under normal conditions.
Nonspecific and specific defense mechanisms pro-
tect the lung from environmental pathogens. Coughing
and sneezing as well as the mucociliary blanket remove
most of the larger particulates from the upper airways.
The innate immune system is very well developed in
the deeper parts of the lung and is made up of a humoral
arm (lactoferrins, lyzozyme, surfactant proteins, man-
nose binding lectin, and defensins) and a cellular arm,
consisting mainly of alveolar macrophages that express
numerous pattern recognition receptors for foreign anti-
gen. If these nonspecific mechanisms fail, a highly de-
veloped network of epithelial and alveolar dendritic cells
(DCs) is responsible for mounting the adaptive immune
response. It has been estimated that the pool of alveolar
macrophages can handle up to 109 intratracheallyinjected bacteria before there is ‘‘spillover’’ of bacteria
to DCs and before adaptive immunity is induced (Ma-
cLean et al., 1996).
Macrophages are specialized hematopoietic cells dis-
tributed throughout different tissues of the body where
they play a central role in homeostasis, tissue remodel-
ing, host defense, and the response to foreign materials,
including particulates. One of the key functional charac-
teristics of macrophages is that, depending on their
state of differentiation and microenvironmental factors
they encounter in a particular tissue, they can be specif-
ically modified to have whatever functions needed to
deal most effectively with a particular inciting stimulus.
In the lung, resident alveolar macrophages are continu-
ously encountering inhaled substances due to their ex-
posed position in the alveolar lumen (Figure 1). To avoid
collateral damage to type I and type II cells in response
to harmless antigens, they are kept in a quiescent state,
producing little inflammatory cytokines and displaying
poor phagocytic activity, as evidenced by downregu-
lated expression of the phagocytic receptor CD11b
(Holt, 1978). In addition, alveolar macrophages actively
suppress the induction of adaptive immunity through
their effects on alveolar and interstitial DCs and T cells.
Elegant studies have demonstrated that in vivo elimina-
tion of alveolar macrophages using clodronate-filled li-
posomes leads to overt inflammatory reactions to other-
wise harmless particulate and soluble antigens (Thepen
et al., 1989). Alveolar macrophages adhere closely to
AECs at the alveolar wall and are separated by a distance
of only 0.2–0.5 mm from interstitial DCs. In macrophage-
depleted mice, the DCs have a clearly enhanced anti-
gen-presenting function (Holt et al., 1993). When mixed
with DCs in vitro, alveolar macrophages suppress T cell
activation through release of nitric oxide (mainly in ro-
dents), prostaglandins, interleukin-10 (IL-10), and trans-
forming growth factor-b (TGFb).
Until recently, it was largely unknown how the lung
environment instructs alveolar macrophages to sup-
press innate and adaptive immunity. A few years ago,
an important step forward was made by the finding that
avb6 integrin-deficient mice have activated alveolar
macrophages due to a lack of TGFb activation in the
lung (Morris et al., 2003). This integrin has the potential
to activate latent TGFb by binding to the latency
associated peptide (LAP), an N-terminal inactivating
fragment of TGFb. Takabayshi et al. in this issue of
Immunity further build on these early findings and dem-
onstrate how the avb6 integrin-TGFb axis influences im-
mune homeostasis in the lung (Takabayashi et al., 2006).
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367Figure 1. Alveolar Macrophages Push and
Release the Brakes on Lung Immunity
In baseline conditions (1), alveolar macro-
phages closely adhere to alveolar epithelial
cells, in this way inducing the expression of
the avb6 integrin, a TGFb-activating integrin.
Upon recognition of dangerous antigens by
TLR triggering, macrophages detach from al-
veolar epithelial cells, and avb6 integrin ex-
pression is rapidly lost. In this way, macro-
phages escape TGFb inhibition and display
innate immune functions such as phagocyto-
sis and secretion of proinflammatory cyto-
kines (2). After a few days, activated T cells
stimulate macrophage production of MMP-
9, which activates latent TGFb and puts the
brake back on the alveolar macrophage,
and eventually, homeostasis is restored (3).They show that under homeostatic conditions alveolar
macrophages closely adhere to AECs, and this in turn
induces the expression of the integrin avb6 on AECs,
in a TGFb-dependent manner, thus leading to localized
activation of TGFb in the vicinity of the macrophage
(Figure 1). Binding of activated TGFb to its receptors ex-
pressed on macrophages induces phosphorylation of
SMAD-2 and -3 and suppresses macrophage phagocy-
tosis and cytokine production. The inhibition of macro-
phage function by avb6-TGFb complex is unique to the
lung, illustrating the microenvironmental specialization
of macrophages to meet the needs of the tissue.
The tonic inhibition of macrophage function in the
lung is so robust that it has long been enigmatic how in-
fection might lead to macrophage activation. Takabay-
shi et al. (2006) show that infectious agents known to
trigger Toll-like receptors (TLRs) and nonpattern recog-
nition receptors on macrophages open a window of op-
portunity for macrophage activation. TLR stimulation of
macrophages leads to a rapid loss of contact with
AECs, which in turn induces a rapid loss of expression
of avb6 integrin expression on AECs (Figure 1). Under
these conditions, TGFb is no longer activated, releasing
the brakes on macrophage activation and innate im-
mune function, and macrophages become primed to
secrete proinflammatory cytokines (tumor necrosis fac-
tor and IL-6) and to phagocyose particulate matter.
Once activated, alveolar macrophages can clear the in-
fectious threat on their own (Takabayashi et al., 2006).
Others had already shown that many infectious agents
induce the recruitment of CCR2+ inflammatory mono-
cytes to the alveolar space (Warmington et al., 1999).
These freshly recruited monocytes are clearly proin-
flammatory and display phagocytosis and killing and
promote rather than suppress T cell and DC activation.
It takes a few days before these monocytes acquire the
suppressive phenotype of alveolar macrophages, al-
lowing for another ‘‘window of opportunity’’ for initiation
of innate and adaptive responses in the lung (Bilyk and
Holt, 1995).To avoid collateral damage and to restore gas ex-
change as quickly as possible, there needs to be a rapid
mechanism to put the brakes back on macrophage acti-
vation, and again, the macrophage is in the driver seat.
Takabayshi et al. (2006) show that a few days after deliv-
ery of the infectious threat activated lymphocytes se-
creting IFN-g stimulate the production of matrix metallo-
proteinase MMP-9 by macrophages (Figure 1). MMP-9
has the potential to activate latent TGFb, and in this
way, tonic inhibition of macrophage function is restored
(as evidenced by the return of SMAD-2 and SMAD-3
phosphorylation), macrophages again adhere to AECs,
and avb6-integrin expression is restored. It has been
described previously by Holt et al. that freshly recruited
monocytes gradually acquire the phenotype of resident
suppressive alveolar macrophages over a period of days
(Bilyk and Holt, 1993). Whether this would be a prede-
fined process or an instruction by the lung TGFb-rich en-
vironment remains to be shown. Certainly, the prolonged
presence of activating cytokines such as GM-CSF keeps
inflammatory monocytes from acquiring suppressive
activities (Bilyk and Holt, 1993). An additional advantage
of enhanced TGFb production would be the stimulation
of collagen synthesis in interstitial fibroblasts, necessary
for restoring alveolar wall architecture.
The findings of Takabayshi et al. have implications for
understanding immunologically mediated lung dis-
eases. Lung fibrosis can not only occur after severe lung
infections but also as an idiopathic disease (Gross and
Hunninghake, 2001). One consistent finding of these
diseases is a loss of type I AEC and a concomitant
hyperplasia of type II AECs. In fibrotic lung disease,
the amounts of activated TGFb are strongly enhanced,
yet alveolar macrophages are persistently activated,
producing too much TNF, IL-1, and IL-6. If type I AECs
are lost, this might lead to a loss of anchoring points
for alveolar macrophages and for avb6. In this way,
macrophages miss an important feedback mechanism
and produce their toxic products that inflict collateral
damage. At the same time, persistent MMP-9 activation
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368and active TGFb might lead to prolonged activation of
fibroblasts and fibrosis.
Takabayshi et al. (2006) have provided important in-
sights into how macrophage innate immune function is
closely regulated in the demanding environment of the
lung. In the future, it will be important to study if the
avb6 integrin-TGFb–macrophage axis also slows down
adaptive immunity and its DC control in homeostatic
conditions. This scenario is certainly a possibility, as
mice deficient in Runx3, another downstream signaling
molecule involved in TGFb signaling, have constitutively
activated alveolar DCs that mount immune responses to
otherwise harmless environmental antigens (Fainaru
et al., 2004). Clearly, more research will be needed be-
fore we understand the full impact of this important
new pathway in lung immune homeostasis.
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